Table 1.
Main patient features.
| Features | % (n) |
|---|---|
| Median age (range) | 56 (35–75) years |
| Male | 52 (14) |
| Female | 48 (13) |
| Type of melanoma | |
| Cutaneous | 85 (23) |
| Unknown origin | 15 (4) |
| Molecular status | |
| BRAF V600 | 67 (18) |
| NRAS Q61 | 7 (2) |
| Wild type | 26 (7) |
| DFS median (range) | 16 (0–360) months |
| M stage | |
| M1a | 33 (9) |
| M1b | 26 (7) |
| M1c | 15 (4) |
| M1d | 26 (7) |
| Systemic therapy | |
| PD1 inhibitors | 48 (13) |
| Targeted therapy | 52 (14) |
| Line of therapy | |
| First line | 41 (11) |
| Second line | 33 (9) |
| Third line | 26 (7) |
| Best response | |
| Complete response | 33 (9) |
| Partial response | 56 (15) |
| Stable disease | 11 (3) |
| Sites of oligoprogression | |
| Skin | 19 (5) |
| Lymph nodes | 30 (8) |
| Liver and gallbladder | 7 (2) |
| Bowel | 7 (2) |
| Brain | 37 (10) |
| Number of progressed metastases | |
| 1 | 59(16) |
| 2 | 26 (7) |
| 3 | 15(4) |
| Local therapy | |
| Surgery | 52 (14) |
| Radiotherapy | 41 (11) |
| Electrochemotherapy | 7 (2) |
| LDH at oligoprogression | |
| Under the upper limits of normal | 48 (13) |
| Over the upper limits of normal | 52 (14) |
| Eastern Cooperative Oncology Group (ECOG) performance status (PS) | |
| 0 | 63 (17) |
| 1 | 33 (9) |
| 2 | 4 (1) |
| Neutrophils to lymphocytes ratio | |
| <2 | 48 (13) |
| >2<3 | 30 (8) |
| >3 | 22 (6) |